https://i.vimeocdn.com/video/2024807511-037e130db6faf4eccabc3ddd4f7fb6e99dac4be253a1817e2dfdf8be46ddb3d9-d

Transforming the treatment of colorectal cancer

Adeno is targeting the root cause of colorectal cancer without harming healthy tissues.

Over 90% of colorectal cancers are driven by Wnt signaling, yet decades of efforts to inhibit the Wnt signaling pathway have failed in the clinic. Adeno is unlocking Wnt targeting with the first tumor-selective approach, eliminating cancer while sparing healthy tissues.

Team Announcement Coming Soon

Joe Sedlak, MD, PhD

CEO

Harvard MD/PhD

Harvard Blavatnik Fellow

Founding CEO, Mercy BioAnalytics, which has raised $68M+, achieving FDA Breakthrough Device Designation ‘24.

Ken Ford, PhD, PE

VP of Manufacturing

28+ years of CMC and formulation experience

Five FDA approvals

Get in Touch

Adeno is located in the Pagliuca Harvard Life Lab

127 Western Ave, Allston, MA 02134, USA

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept